Mostrar el registro sencillo del ítem

dc.creatorPetry, N. M.
dc.creatorRehbein, F.
dc.creatorGentile, D. A.
dc.creatorLemmens, J. S.
dc.creatorRumpf, H. J.
dc.creatorMossle, T.
dc.creatorBischof, G.
dc.creatorTao, R.
dc.creatorFung, D. S. S.
dc.creatorBorges, G.
dc.creatorAuriacombe, M.
dc.creatorGonzalezibanez, A.
dc.creatorTam, P.
dc.creatorO'Brien, C. P.
dc.date.accessioned2017-06-29T03:54:39Z
dc.date.available2017-06-29T03:54:39Z
dc.date.issued2014es_ES
dc.identifier2776es_ES
dc.identifier.issn0965-2140es_ES
dc.identifier.urihttp://repositorio.inprf.gob.mx/handle/123456789/4625
dc.identifier.urihttps://doi.org/10.1111/add.12549es_ES
dc.description.abstractes_ES
dc.language.isoenges_ES
dc.publisherOxford : Wiley-Blackwelles_ES
dc.relation109 (9) 1567-1568 p.es_ES
dc.relationversión del editores_ES
dc.rightsacceso cerradoes_ES
dc.subject.meshBehavior, Addictive/diagnosises_ES
dc.subject.meshConsensuses_ES
dc.subject.meshDiagnostic and Statistical Manual of Mental Disorderses_ES
dc.subject.meshHumanses_ES
dc.subject.meshInternationalityes_ES
dc.subject.meshVideo Games/psychologyes_ES
dc.titleInternet gaming and addiction: a reply to King & Delfabbroes_ES
dc.title.alternativees_ES
dc.typeartículoes_ES
dc.contributor.affiliationUniversity of Connecticut School of Medicine, Farmington, CT, USA.es_ES
dc.contributor.emailnpetry@uchc.edues_ES
dc.relation.jnabreviadoADDICTIONes_ES
dc.relation.journalAddiction es_ES
dc.identifier.placeInglaterraes_ES
dc.date.published2014es_ES
dc.identifier.organizacionInstituto Nacional de Psiquiatría Ramón de la Fuente Muñizes_ES
dc.identifier.eissn1360-0443es_ES
dc.identifier.doi10.1111/add.12549es_ES
dc.description.monthSepes_ES
dc.description.abstractotrodiomaOBJECTIVE:  Second-generation antipsychotics (SGAs) are among the first-line treatments for bipolar disorder and schizophrenia, but have a tendency to generate metabolic disturbances. These features resemble a metabolic syndrome for which a central autonomic imbalance has been proposed that may originate from the hypothalamic suprachiasmatic nuclei. In a clinical trial, we hypothesized that melatonin, a hormone that regulates the suprachiasmatic nucleus, could attenuate SGA-induced adverse metabolic effects. METHODS:  In an eight-week, double-blind, randomized, placebo-controlled, parallel-group clinical trial, we evaluated the metabolic effect of melatonin in SGA-treated patients in terms of weight, blood pressure, lipid, glucose, body composition, and anthropometric measures. A total of 44 patients treated with SGAs, 20 with bipolar disorder and 24 with schizophrenia, randomly received placebo (n = 24) or melatonin 5 mg (n = 20). RESULTS:  The melatonin group showed a decrease in diastolic blood pressure (5.1 versus 1.1 mmHg for placebo, p = 0.003) and attenuated weight gain (1.5 versus 2.2 kg for placebo, F = 4.512, p = 0.040) compared to the placebo group. The strong beneficial metabolic effects of melatonin in comparison to placebo on fat mass (0.2 versus 2.7 kg, respectively, p = 0.032) and diastolic blood pressure (5.7 versus 5.5 mmHg, respectively, p = 0.001) were observed in the bipolar disorder and not in the schizophrenia group. No adverse events were reported. CONCLUSIONS:  Our results show that melatonin is effective in attenuating SGAs' adverse metabolic effects, particularly in bipolar disorder. The clinical findings allow us to propose that SGAs may disturb a centrally mediated metabolic balance that causes adverse metabolic effects and that nightly administration of melatonin helps to restore. Melatonin could become a safe and cost-effective therapeutic option to attenuate or prevent SGA metabolic effects.  es_ES
dc.subject.meshmes_ES
dc.subject.kwes_ES
dc.subject.koAddictiones_ES
dc.subject.koBehavioral Addictiones_ES
dc.subject.koDiagnosises_ES
dc.subject.koGambling Disorderses_ES
dc.subject.koInternet Gaminges_ES
dc.subject.koTreatmentes_ES


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem